INDO US BIOTECH
|
INDO US BIOTECH Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.11 | 4.12 | 7.22 | 5.71 | 8.40 |
| CEPS(Rs) | 8.66 | 4.51 | 4.02 | 3.09 | 3.67 |
| DPS(Rs) | 0.25 | - | - | - | - |
| Book NAV/Share(Rs) | 39.16 | 31.29 | 54.35 | 42.41 | 35.47 |
| Tax Rate(%) | 1.59 | 6.28 | 1.98 | 4.60 | -23.53 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.24 | 14.83 | 15.21 | 13.85 | 13.75 |
| EBIT Margin(%) | 17.35 | 14.17 | 13.91 | 13.37 | 13.24 |
| Pre Tax Margin(%) | 15.92 | 12.09 | 11.96 | 10.97 | 10.29 |
| PAT Margin (%) | 15.67 | 11.33 | 11.73 | 10.46 | 12.72 |
| Cash Profit Margin (%) | 16.72 | 12.43 | 13.06 | 11.31 | 13.34 |
| Performance Ratios | |||||
| ROA(%) | 17.98 | 10.81 | 11.67 | 10.63 | 13.05 |
| ROE(%) | 23.03 | 14.08 | 15.51 | 17.34 | 26.87 |
| ROCE(%) | 21.15 | 14.42 | 14.62 | 15.86 | 18.30 |
| Asset Turnover(x) | 1.15 | 0.95 | 1.00 | 1.02 | 1.03 |
| Sales/Fixed Asset(x) | 12.27 | 10.36 | 9.57 | 12.72 | 21.43 |
| Working Capital/Sales(x) | 1.48 | 1.31 | 1.30 | 1.44 | 1.99 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.08 | 0.10 | 0.10 | 0.08 | 0.05 |
| Receivable days | 59.84 | 109.71 | 133.85 | 164.93 | 207.92 |
| Inventory Days | 215.16 | 197.06 | 148.59 | 128.48 | 95.73 |
| Payable days | 597.69 | -53.89 | 302.49 | -222.52 | - |
| Valuation Parameters | |||||
| PER(x) | 18.15 | 53.94 | 14.71 | 5.91 | 3.23 |
| PCE(x) | 17.00 | 49.17 | 26.41 | 10.93 | 3.69 |
| Price/Book(x) | 3.76 | 7.09 | 3.91 | 1.59 | 0.92 |
| Yield(%) | 0.17 | - | - | - | - |
| EV/Net Sales(x) | 2.98 | 6.29 | 3.64 | 1.48 | 0.78 |
| EV/Core EBITDA(x) | 16.21 | 41.20 | 23.84 | 10.45 | 5.60 |
| EV/EBIT(x) | 17.19 | 44.39 | 26.14 | 11.11 | 5.86 |
| EV/CE(x) | 3.32 | 5.95 | 3.40 | 1.35 | 0.72 |
| M Cap / Sales | 2.84 | 6.11 | 3.45 | 1.24 | 0.49 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 42.56 | 17.96 | 23.36 | 24.86 | 0.82 |
| Core EBITDA Growth(%) | 71.86 | 18.17 | 32.33 | 28.02 | 39.92 |
| EBIT Growth(%) | 74.56 | 20.21 | 28.35 | 26.10 | 41.59 |
| PAT Growth(%) | 97.15 | 13.96 | 38.25 | 2.73 | 101.13 |
| EPS Growth(%) | 97.15 | -43.02 | 26.40 | -31.99 | 101.13 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.19 | 0.23 | 0.21 | 0.32 | 0.53 |
| Current Ratio(x) | 5.31 | 4.19 | 4.87 | 3.85 | 2.12 |
| Quick Ratio(x) | 0.98 | 1.22 | 2.68 | 1.94 | 1.46 |
| Interest Cover(x) | 12.09 | 6.79 | 7.15 | 5.57 | 4.50 |
| Total Debt/Mcap(x) | 0.05 | 0.03 | 0.05 | 0.20 | 0.58 |
Compare Financial Ratios of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹270.1 Cr | -1.5% | -1.1% | -40.7% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹13,817.6 Cr | -2.6% | 11.7% | -25.9% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,343.8 Cr | -2% | -1.2% | 24.6% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,133.4 Cr | 4.1% | 1.7% | -9.2% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,282.9 Cr | -2.6% | -3.5% | -23.9% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹471.3 Cr | -4.9% | -10.2% | NA | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -1.5% |
-1.1% |
-40.7% |
| SENSEX | -0.3% |
4.5% |
5.7% |
You may also like the below Video Courses
